Saleh Hassan, Sharma Divyansh, Afify Hesham, Sharma Ravi, Ikram Sohail, Solankhi Naresh
Department of Medicine, Division of Cardiology, School of Medicine, University of Louisville, Louisville, Kentucky, USA.
Division of Cardiology, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, Nevada, USA.
Catheter Cardiovasc Interv. 2025 Sep;106(3):1584-1590. doi: 10.1002/ccd.31724. Epub 2025 Jun 27.
Coronary calcified nodules (CNs) are a challenging subset of calcific lesions associated with adverse procedural outcomes. While rotational atherectomy (RA) and balloon angioplasty (BA) have been traditionally used, orbital atherectomy (OA) offers a unique mechanism of plaque modification that may be advantageous in the treatment of CNs. Data on OA in CNs remains limited.
To evaluate procedural success, periprocedural safety, in-hospital and long-term outcomes of retrograde OA in the treatment of CNs.
We conducted a retrospective analysis of all patients who underwent OA for angiographically identified coronary calcification between January 1, 2022 and March 31, 2024. A total of 312 patient underwent OA during this period, of whom 57 had a CN identified. Baseline demographics, lesion characteristics, procedural details, and outcomes were assessed. CNs were defined by angiographic or intravascular ultrasound appearance.
The mean age was 71, 71.9% were male, 71.9% had diabetes, 40.3% had CKD and 15.8% had prior coronary artery bypass. The majority of lesions involved the left anterior descending artery (49.1%). Retrograde treatment using a 1.25 mm burr at 80,000 rpms was exclusively used. Angiographic success was achieved in 100% of cases. No perforations or flow-limiting dissections were observed. During an average follow-up of 325.57 ± 233.45 days, there were no cases of early or late stent thrombosis, with one case of very late stent thrombosis. Major adverse cardiac events (MACE) occurred in 5.26% (three patients), comprising myocardial infarction in 3.51% (two patients) and target vessel revascularization in 1.75% (one patient).
In this real-world, single-center, retrospective analysis, OA was safe and effective in treating coronary CNs, achieving high angiographic success with minimal periprocedural complications. These findings support the use of OA as a viable strategy for CNs, though further studies are warranted.
冠状动脉钙化结节(CNs)是与不良手术结果相关的具有挑战性的钙化病变子集。虽然传统上使用旋磨术(RA)和球囊血管成形术(BA),但轨道旋磨术(OA)提供了一种独特的斑块修饰机制,在治疗CNs方面可能具有优势。关于OA治疗CNs的数据仍然有限。
评估逆行OA治疗CNs的手术成功率、围手术期安全性、住院和长期结果。
我们对2022年1月1日至2024年3月31日期间因血管造影确定的冠状动脉钙化而接受OA治疗的所有患者进行了回顾性分析。在此期间,共有312例患者接受了OA治疗,其中57例被确定有CN。评估了基线人口统计学、病变特征、手术细节和结果。CNs由血管造影或血管内超声表现定义。
平均年龄为71岁,71.9%为男性,71.9%患有糖尿病,40.3%患有慢性肾脏病,15.8%曾接受过冠状动脉搭桥术。大多数病变累及左前降支(49.1%)。仅使用1.25毫米磨头以80000转/分钟进行逆行治疗。100%的病例实现了血管造影成功。未观察到穿孔或血流限制性夹层。在平均325.57±233.45天的随访期间,没有早期或晚期支架血栓形成的病例,有1例极晚期支架血栓形成。主要不良心脏事件(MACE)发生率为5.26%(3例患者),包括3.51%(2例患者)的心肌梗死和1.75%(1例患者)的靶血管血运重建。
在这项真实世界、单中心、回顾性分析中,OA治疗冠状动脉CNs安全有效,血管造影成功率高,围手术期并发症最少。这些发现支持将OA作为治疗CNs的可行策略,不过仍需进一步研究。